Movement Alert｜ImmunityBio, Inc. Rises 5.23% in Regular Trading, trading at 8.85 USD

Market Focus10-21

On October 21, ImmunityBio, Inc. rose 5.23% in Regular Trading, trading at 8.85 USD/share, with Turnover of 58.9663 million USD.

Within the Biotechnology sector where ImmunityBio, Inc. belongs, peer stocks also moved higher, including Moderna, Inc. up 4.0%, AbbVie up 2.27%, Gilead Sciences up 1.52%, Amgen up 2.23%, and Argenx SE up 6.28%.

The company previously reported June-quarter results on August 4, with adjusted EPS of negative 0.08 beating the consensus estimate of negative 0.09 and revenue of 51.24 million USD above the 49.7 million USD estimate, although reported net loss widened to 0.22 USD per diluted share. Earlier in July, Anktiva also received marketing authorization in the UAE for certain bladder and lung cancer indications. These developments provide background on the company, but no fresh company-specific catalyst is identified in the latest movement data.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment